

Tocilizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

NCT04561986

Status	RECRUITING
Phase	Phase 3
Sponsor	Vastra Gotaland Region
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (12)

- The subject has given their written informed consent to participate in the study
- Recipient of living donor or deceased donor kidney transplant
- Age ≥18 years
- At least 6 months post-transplantation at randomization
- Biopsy-proven diagnosis of late active or chronic active ABMR (≥6 months after transplantation) according to the Banff 2022 criteria in index biopsy
- ... and 7 more (see full listing online)

Exclusion (20)

- Recipient of multi-organ transplants
- De novo or recurrent renal disease that is considered to be the predominant cause of the current graft dysfunction
- Active viral infections such as BK virus (BKV), cytomegalovirus (CMV), EBV, COVID-19, hepatitis C virus (HCV) or hepatitis B virus (HBV) infections based on polymerase chain reaction (PCR) testing
- Ongoing serious infections as per Investigator's opinion
- History of recurrent infections requiring hospitalization
- ... and 15 more (see full listing online)

Locations (8 total)

Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Hospital del Mar, Barcelona, Spain
Marqués de Valdecilla Research Institute, Santander, Spain
... and 5 more locations

<https://clinicaltrials.gov/study/NCT04561986>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).